15 Words From Vertex's CEO That Signal Major Growth Ahead
Here's the one big worry a lot of investors have about Vertex Pharmaceuticals (NASDAQ: VRTX) these days: revenue prospects beyond its main cystic fibrosis (CF) business. Right now, the company's only commercialized treatments are in CF. Vertex is moving candidates through the pipeline in other areas such as blood disorders, pain, and a rare lung and liver disorder called alpha-1 antitrypsin deficiency. But so far, those pipeline programs haven't eased investors' concerns. The stock has tumbled nearly 15% since the start of the year.
Of course, as a shareholder I'd like to see Vertex bring one or more of those potential products to market. But it's important to remember that the CF story is far from over. Proof of that? Here are 15 words from Vertex CEO Reshma Kewalramani that signal major growth ahead for the CF business...
Image source: Getty Images.
Source Fool.com
